Halozyme Therapeutics, Inc. $HALO Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd trimmed its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 82.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,901 shares of the biopharmaceutical company’s stock after selling 77,700 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Halozyme Therapeutics were worth $1,240,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in the business. Empowered Funds LLC purchased a new stake in Halozyme Therapeutics during the first quarter worth approximately $755,000. Acadian Asset Management LLC acquired a new stake in Halozyme Therapeutics during the first quarter worth approximately $195,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Halozyme Therapeutics by 15.5% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,760 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 639 shares in the last quarter. QRG Capital Management Inc. lifted its position in shares of Halozyme Therapeutics by 14.6% during the 2nd quarter. QRG Capital Management Inc. now owns 5,055 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 644 shares during the last quarter. Finally, 111 Capital acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $689,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Down 2.2%

HALO opened at $71.71 on Friday. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $79.50. The business has a 50 day moving average price of $68.93 and a two-hundred day moving average price of $68.45. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59. The company has a market cap of $8.43 billion, a PE ratio of 15.10, a P/E/G ratio of 0.32 and a beta of 0.94.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.09. The company had revenue of $354.26 million for the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.During the same period last year, the business posted $1.27 EPS. The company’s revenue was up 22.1% on a year-over-year basis. As a group, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics News Roundup

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Preliminary 2025 results beat expectations and management raised 2026 outlook — the upbeat update helped push shares higher on Jan. 29 as revenue and profitability momentum improved, supporting the company’s longer‑term earnings trajectory. HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance
• Positive Sentiment: Halozyme announced an acquisition of Surf Bio for up to $400M — this expands its pipeline/technology footprint tied to the ENHANZE platform and is a strategic revenue/pipeline bolt‑on that can accelerate growth if integrations and deal economics play out as expected. Halozyme Acquires Surf Bio for up to $400M
• Positive Sentiment: H.C. Wainwright reiterated a Buy rating and kept a $90 price target — a prominent sell‑side endorsement that supports upside vs. current levels and highlights confidence in the ENHANZE platform’s commercial contribution. H.C. Wainwright Sees Strength in Halozyme Therapeutics’ ENHANZE Platform, Reiterates Buy Rating
• Positive Sentiment: Market commentary highlights HALO as a momentum name based on style scores and recent earnings/guidance — this can attract momentum and quant flows. Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
• Neutral Sentiment: A valuation/markets piece examines whether HALO still offers value after multi‑year gains — useful context for longer‑term investors weighing current price vs. growth expectations. Is Halozyme Therapeutics (HALO) Offering Value After Strong Multi‑Year Share Price Gains
• Negative Sentiment: Zacks Research issued minor downward tweaks to several near‑term quarterly EPS estimates and kept a “Hold” stance — small cuts to Q2 2026 and Q3 2027 forecasts (and only tiny upward tweaks to other quarters) may have trimmed near‑term sentiment and contributed to selling/profit taking. (Zacks updates consolidated from analyst notes.)

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $69.13, for a total value of $1,382,600.00. Following the transaction, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at approximately $50,721,994.47. The trade was a 2.65% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of the firm’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $68.48, for a total transaction of $136,960.00. Following the completion of the sale, the director owned 42,952 shares of the company’s stock, valued at $2,941,352.96. This trade represents a 4.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 41,398 shares of company stock worth $2,861,352. 2.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

HALO has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday. Weiss Ratings downgraded Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research report on Monday, October 27th. Finally, Citizens Jmp lifted their price target on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $78.80.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.